Recent

% | $
Quotes you view appear here for quick access.

Crestwood Midstream Partners LP Message Board

twojugglers 202 posts  |  Last Activity: Sep 28, 2016 1:13 AM Member since: Apr 6, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Sep 27, 2016, 11:50 am EDT | By Lucas Hahn, InvestorPlace Contributor

    "San Diego-based Organovo Holdings Inc (NASDAQ:ONVO) prints 3D human liver and kidney tissue models. Organovo’s 3D human tissue holds the potential to revolutionize drug discovery and development. Clinical trials often fail due to toxicity, but ONVO’s tissue models could help predict this and save Big Pharma millions of dollars.

    Pharmaceutical companies spend over $50 billion a year on research and development, and Organovo estimates the markets for liver and kidney toxicology testing at $1.3 billion and $2.1 billion, respectively. Further down the road, ONVO’s 3D printed tissue could be used for therapeutic implants.

    Does Organovo meet the conditions of a takeover target? ONVO is at the center of an emerging industry, developing a potentially game-changing product. Organovo enjoys a clean balance sheet, with no debt or stock with super voting rights that could block an acquisition.

    ONVO partners with academic institutions such as the Harvard Medical School, as well as Big Pharma, including Merck & Co., Inc. (NYSE:MRK), Bristol-Myers Squibb Co (NYSE:BMY) and United Therapeutics Corporation (NASDAQ:UTHR). L’Oreal SA (ADR) (OTCMKTS:LRLCY) also formed a partnership with ONVO to develop skin tissue to test cosmetics. These firms might acquire Organovo in the future in order to gain a competitive advantage in the industry.

    The Motley Fool’s Brian Stoffel thinks Organovo could be bought out for $1 billion if the technology proves itself. Currently, the market values ONVO at just over $360 million."

    Well, the technology HAS PROVEN itself, but I'm not hoping for a buyout, certainly not at 3 or 4 times the current price.

    Juggsy

    Sentiment: Strong Buy

  • twojugglers twojugglers Sep 28, 2016 12:35 AM Flag

    Here are ETF's that track the Nasdaq Biotechnology Index:

    iShares Nasdaq Biotechnology Index Fund IBB BlackRock Institutional Trust Company, N.A.

    ProShares Ultra NASDAQ Biotechnology ETF BIB ProShares Trust
    Since July the above fund has gone from $40/sh up to $51.32

    ProShares UltraShort NASDAQ Biotechnology ETF BIS ProShares Trust
    Since July the above fund has gone from $40/sh down to $29.37, so this is the one Toppa will be most interested in.

    Tachlit Nasdaq Biotechnology ILS TCBI105 Tachlit Trackers
    Mirae Asset TIGER Nasdaq BIO ETF 203780 Mirae Asset MAPS Global Investment Co., Ltd
    Source NASDAQ Biotech UCITS ETF SBIO Source UK Services Limited
    ProShares UltraPro Nasdaq Biotechnology ETF UBIO ProShares Trust
    ProShares UltraProShort Nasdaq Biotechnology ETF ZBIO ProShares Trust

    So, some of these funds will be buying shares of Organovo, and some will be shorting. Will certainly add volume.

    Sentiment: Strong Buy

  • Reply to

    ReTweet

    by whp0three Sep 26, 2016 5:38 PM
    twojugglers twojugglers Sep 26, 2016 8:50 PM Flag

    You can view three of the slides Dr. David used in his presentation here:

    https://twitter.com/savingcase

    The 3rd one in interesting.

    Sentiment: Strong Buy

  • twojugglers by twojugglers Sep 23, 2016 10:32 PM Flag

    Applewood Road
    Motel Mirrors.  The Mercy Project.
    The Ghost of Johnny Cash.

    Sentiment: Strong Buy

  • Reply to

    Confessions of an ONVO junkie....

    by ournightowl Sep 23, 2016 12:47 PM
    twojugglers twojugglers Sep 23, 2016 6:37 PM Flag

    Hello, I'm Juggsy
    I'm a Yahoo chat board junkie
    Onvo is cool too

    Sentiment: Strong Buy

  • Reply to

    Confessions of an ONVO junkie....

    by ournightowl Sep 23, 2016 12:47 PM
    twojugglers twojugglers Sep 23, 2016 6:20 PM Flag

    Was in a bookstore today perusing used Haiku books. Liked this one:

    The fat lady
    Bends over the tomatoes
    A full moon

    Those camellias
    Grown by the town embalmer
    Won the prize again

    Sentiment: Strong Buy

  • Reply to

    Confessions of an ONVO junkie....

    by ournightowl Sep 23, 2016 12:47 PM
    twojugglers twojugglers Sep 23, 2016 5:06 PM Flag

    Back at ya Owlie
    Never can have too many
    Friends like you watching my back

    Sentiment: Strong Buy

  • Reply to

    Confessions of an ONVO junkie....

    by ournightowl Sep 23, 2016 12:47 PM
    twojugglers twojugglers Sep 23, 2016 4:17 PM Flag

    Then tis sweet revenge
    To feast on a tasty piece
    Of those loathsome creeps

    Sentiment: Strong Buy

  • Reply to

    Confessions of an ONVO junkie....

    by ournightowl Sep 23, 2016 12:47 PM
    twojugglers twojugglers Sep 23, 2016 3:57 PM Flag

    Cows do moo and chew
    Grass and even dear Toppa
    A bitter mouthful .

    Sentiment: Strong Buy

  • Reply to

    Confessions of an ONVO junkie....

    by ournightowl Sep 23, 2016 12:47 PM
    twojugglers twojugglers Sep 23, 2016 3:41 PM Flag

    Juggsy watches as
    Organovo marches on
    Slaying detractors

    Sentiment: Strong Buy

  • Reply to

    Confessions of an ONVO junkie....

    by ournightowl Sep 23, 2016 12:47 PM
    twojugglers twojugglers Sep 23, 2016 3:27 PM Flag

    Toppa and his ilk
    Crying over the spilt milk
    Of their ruined lives.

    Sentiment: Strong Buy

  • twojugglers by twojugglers Sep 22, 2016 7:33 PM Flag

    I'm at the Americana Music Awards, listening to Bob Weir debut his first album in 30 years, but zi had to check for anything new on Organovo. Found the Speights article 3 minutes after it was released.

    Great music here in Nashville!

    Sentiment: Strong Buy

  • On Motley Fool.
    It's accurate and cautiously positive.
    Nothing new of course.
    May interest a few retail investors.

    Sentiment: Strong Buy

  • Reply to

    The stock scoop

    by cashmoo2 Sep 20, 2016 4:23 PM
    twojugglers twojugglers Sep 21, 2016 4:21 PM Flag

    MoPower,

    I'very been trading 10,000 shares for a few weeks now. Set my cap gains to Last in, first out. It's been working out so far....

    Sentiment: Strong Buy

  • twojugglers twojugglers Sep 20, 2016 9:54 AM Flag

    Thank Owl,

    I knew you'd get it. This truly is the Brave New World.

    Sentiment: Strong Buy

  • Co-Authored by Alice Chen, Associate Director R&D- Tissue Applications at Organovo

    Accepted manuscript online: 15 September 2016

    Abstract

    Cellular reprogramming by epigenomic remodeling of chromatin holds great promise in the field of human regenerative medicine. As an example, human induced Pluripotent Stem Cells (iPSCs) obtained by reprograming of patient somatic cells are sufficiently similar to embryonic stem cells (ESCs) and can generate all cell types of the human body. Clinical use of iPSCs is dependent on methods that do not utilize genome altering transgenic technologies that are potentially unsafe and ethically unacceptable. Transient delivery of exogenous RNA into cells provides a safer reprogramming system to transgenic approaches that rely on exogenous DNA or viral vectors. RNA reprogrammed iPSCs lines may prove to be more suitable for clinical applications and provide stable starting cell lines for gene-editing, isolation and characterization of patient iPSC lines. The introduction and rapid evolution of CRISPR/Cas9 gene-editing systems has provided a readily accessible research tool to perform functional human genetic experiments. Similar to RNA reprogramming, transient delivery of mRNA encoding Cas9 in combination with guide RNA sequences to target specific points in the genome eliminates the risk of potential integration of Cas9 plasmid constructs. We present optimized RNA based laboratory procedure for making and editing iPSCs. In the near-term these two powerful technologies are being harnessed to dissect mechanisms of human development and disease in vitro, supporting both basic and translational research.

    Sentiment: Strong Buy

  • twojugglers twojugglers Sep 15, 2016 3:23 PM Flag

    They've got a great photo of the Milky Way on their homepage. Still working on their website too, I see. Perhaps preparing for another big push with their deception.

    Sentiment: Strong Buy

  • Cowen Group Inc. increased its position in shares of Organovo Holdings Inc. (NASDAQ:ONVO) by 8.6% during the second quarter, Holdings Channel reports. The fund owned 63,000 shares of the company’s stock after buying an additional 5,000 shares during the period. Cowen Group Inc. owned about 0.07% of Organovo Holdings worth $234,000 at the end of the most recent quarter.
    A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Organovo Holdings by 9.1% in the second quarter. Vanguard Group Inc. now owns 3,376,661 shares of the company’s stock worth $12,561,000 after buying an additional 281,330 shares during the period. Penbrook Management LLC boosted its stake in shares of Organovo Holdings by 35.8% in the second quarter. Penbrook Management LLC now owns 266,475 shares of the company’s stock worth $992,000 after buying an additional 70,250 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Organovo Holdings by 3.9% in the second quarter. Bank of New York Mellon Corp now owns 377,437 shares of the company’s stock worth $1,404,000 after buying an additional 14,315 shares during the period. 19.11% of the stock is currently owned by institutional investors and hedge funds.

    http://www.mideasttime.com/organovo-holdings-inc-onvo-shares-bought-by-cowen-group-inc/1265306.html

    Sentiment: Strong Buy

  • twojugglers twojugglers Sep 14, 2016 5:20 PM Flag

    This is a great interview!

    A must listen.

    Sentiment: Strong Buy

  • twojugglers twojugglers Sep 14, 2016 5:05 PM Flag

    Breakthroughs Are Just the Beginning: How a 3D Bioprinting Pioneer Creates a Market

    https://t.co/Yy0HjWYnLo

    Sentiment: Strong Buy

CMLP
0.00(0.00%)